How much funding has Inhibikase Therapeutics raised?

Inhibikase Therapeutics has raised $110.0M in total funding, most recently a Private Equity round.

Who are Inhibikase Therapeutics's investors?

Inhibikase Therapeutics's investors include Soleus Capital, Sands Capital, Fairmount.

When was Inhibikase Therapeutics founded?

Inhibikase Therapeutics was founded in 2008.

Where is Inhibikase Therapeutics headquartered?

Inhibikase Therapeutics is headquartered in Atlanta, Georgia, United States.

What industry is Inhibikase Therapeutics in?

Inhibikase Therapeutics operates in Biotech, Healthcare.

How many employees does Inhibikase Therapeutics have?

Inhibikase Therapeutics has 11-50 employees.

Inhibikase Therapeutics

IPO

Inhibikase Therapeutics, Inc.

Public · Atlanta, United States · Founded 2008 · $110.0M raised

Biotech

Healthcare

Headquarters: Atlanta, Georgia
Employees: 11–50
Founded: 2008
Business Model: B2B
Website: inhibikase.com

Total Funding: $110.0M
Last Round: $110.0M Private EquityOct 2024
Rounds: 1
Type: Public

About

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH). The company applies Abelson Tyrosine Kinase inhibitor science to address serious cardiovascular and pulmonary diseases, advancing its lead candidate IkT-001Pro through late-stage clinical trials.

Summary

Inhibikase Therapeutics is a Biotech company based in Atlanta, United States, founded in 2008. It has raised $110.0M in total across 1 round, most recently a $110.0M Private Equity round in Oct 2024. Investors include Soleus Capital, Sands Capital and Fairmount.

LinkedIn X (Twitter)

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPONov 2025

$100.0M

Nov 2025

Sign up to see all 2 rounds

Private Equity through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Soleus Capital

Lead

1 round

Sands Capital

1 round

Fairmount

1 round

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare

Growth Equity·$5.1B·Aug 2022

IVI-RMA

IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...

Valencia, Spain5001–10000Biotech, Healthcare

Private Equity·$3.3B·Apr 2022

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech

Series A·$3.0B·Jan 2022

inVentiv HealthAcquired

inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...

Burlington, United States5001–10000Biotech, Healthcare

Private Equity·$3.0B·May 2017

Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare

Private Equity·$3.0B·Jan 2004

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology

Corporate Round·$2.8B·Jan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

<a href="https://indexed.vc/companies/inhibikase-therapeutics"><img src="https://indexed.vc/api/badge/company/inhibikase-therapeutics" alt="Inhibikase Therapeutics on Indexed.vc" width="260" height="76" /></a>